statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Latest Ratings for BMRN
 DateFirmActionFromTo Feb 2022Piper SandlerMaintainsOverweight Nov 2021Credit SuisseMaintainsOutperform Nov 2021Morgan StanleyMaintainsEqual-Weight
 View More Analyst...

Deep Dive Into Biomarin Pharmaceutical Stock: Analyst Perspectives (8 Ratings)

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET BioMarin to Host First Quarter 2024 Financial Results Conference Call and...

BioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Get Free Report) EVP George Eric Davis sold 24,602 shares of the stock in a transaction dated Thursday, March 28th. The shares were sold at an average...

Insider Selling: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) EVP Sells 24,602 Shares of Stock

Looking Into Biomarin Pharmaceutical's Recent Short Interest

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...

Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?

It has been about a month since the last earnings report for Beam Therapeutics Inc. (BEAM). Shares have lost about 22.1% in that time frame, underperforming the S&P 500.Will the recent negative trend...

Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?

Atara Biotherapeutics (ATRA) came out with a quarterly loss of $0.56 per share versus the Zacks Consensus Estimate of a loss of $0.61. This compares to loss of $0.72 per share a year ago. These...

Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates

Gulf International Bank UK Ltd cut its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Free Report) by 9.0% during the fourth quarter, according to the company in its most...

Gulf International Bank UK Ltd Trims Stock Position in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Public Employees Retirement System of Ohio lowered its stake in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Free Report) by 9.0% during the third quarter, according to the company in...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Sold by Public Employees Retirement System of Ohio

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN  Get Free Report) insider Henry J. Fuchs sold 35,341 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Insider Henry J. Fuchs Sells 35,341 Shares

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Volume	624,243.00
52-Wk High	$99.56
52-Wk Low	$76.02

BMRN Biomarin Pharmaceutical Inc. - Registered Shares

About

Feed

News

Sentiment

Earnings

Fundamentals

Sentiment

Message Volume

Community